acamprosate vs cariprazine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and cariprazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Vraylar
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Vraylar is a medicine used to treat certain mental health conditions. It can help with schizophrenia, bipolar disorder, and major depressive disorder.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Vraylar can treat schizophrenia in adults and kids 13 and older. It also treats manic or mixed episodes of bipolar I disorder in adults and kids 10 and older. In adults, Vraylar treats the depressive episodes of bipolar I disorder. Vraylar can also be used with antidepressants to treat major depressive disorder in adults.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Vraylar affects certain chemicals in the brain. These chemicals are called neurotransmitters. By changing the balance of these chemicals, Vraylar can help reduce symptoms of mental health conditions.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Problems with muscle movement
- • Feeling restless
- • Upset stomach
- • Throwing up
- • Feeling sleepy
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Weight Increased 441
- Akathisia 395
- Anxiety 354
- Tardive Dyskinesia 347
- Nausea 331
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Vraylar may increase the risk of death in older adults with dementia-related psychosis. Vraylar and antidepressants can increase suicidal thoughts and behaviors in children, teens, and young adults. Tell your doctor right away if you have thoughts of harming yourself.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Vraylar may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry for women who take Vraylar during pregnancy; you can contact them at 1-866-961-2388.
Also Compare, Nearby Drugs
Compare cariprazine with
How to Read This acamprosate vs cariprazine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while cariprazine sits within the Atypical Antipsychotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while cariprazine has 1,868. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or cariprazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.